Yes, oliceridine (Olinvyk) is an FDA-approved intravenous opioid analgesic that offers a new option for managing severe acute pain. Approved on August 7, 2020, it is intended for patients who have not found relief with other treatments.
Oliceridine is an opioid analgesic used for the management of severe acute pain when other treatments are insufficient. It belongs to the drug class of opioids (narcotic analgesics) and is administered intravenously.
Oliceridine works by binding to the mu-opioid receptor in the brain, altering the perception of pain and emotional response to pain. Unlike traditional opioids, oliceridine is designed to provide effective pain relief with potentially fewer side effects, such as respiratory depression.
Oliceridine is administered intravenously, usually through an infusion pump that allows for continuous dosing. The recommended dosing regimen is as follows:
Initial Dose:
Supplemental Dose:
Maximum Dose:
For patient-controlled analgesia (PCA), the recommended demand dose is 0.35 mg with a 6-minute lockout period, with a maximum of 27 mg per day.
Oliceridine can cause various side effects, ranging from common to severe:
Common Side Effects:
Serious Side Effects:
Oliceridine carries the risk of addiction, overdose, and death, especially when misused or combined with alcohol and other sedatives. Other important precautions include:
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!